Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yelin Mulati

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Frontiers in Oncology|November 1, 2021
Novel Androgen Receptor Inhibitors in Non-Metastatic, Castration-Resistant Prostate Cancer: A Systematic Review and Network Meta-AnalysisYelin Mulati, Yu Fan, Wei Yu, et al.
Frontiers in Oncology|January 27, 2022
Diagnostic Accuracy of Contemporary Selection Criteria in Prostate Cancer Patients Eligible for Active Surveillance: A Bayesian Network Meta-AnalysisYu Fan, Yelin Mulati, Lingyun Zhai, et al.
International Journal of Biological Sciences|January 3, 2024
ZNF471 Interacts with BANP to Reduce Tumour Malignancy by Inactivating PI3K/AKT/mTOR Signalling but is Frequently Silenced by Aberrant Promoter Methylation in Renal Cell CarcinomaXiaofei Wang, Lin Yao, Zheng Li, et al.
World Journal of Urology|January 23, 2026
P.I. nomogram: an exploratory imaging-derived model for predicting early urinary incontinence following ThuLEPXiao-Da Lan, Rui Jiang, He Wang, et al.
Scientific Reports|July 4, 2025
Characterizing PSMA heterogeneity in prostate cancer and identifying clinically actionable tumor associated antigens in PSMA negative casesYelin Mulati, Qi Shen, Yuxuan Tian, et al.
Theranostics|May 7, 2026
Integrated radio-theranostics using a [<sup>89</sup>Zr]Zr-/[<sup>177</sup>Lu]Lu-labeled B7-H3 antibody-drug conjugate for prostate cancerYongkang Qiu, Tingfei Gu, Tianyao Wang, et al.
Prostate Cancer and Prostatic Diseases|December 24, 2025
Systematic profiling of tumor-associated antigen expression for antibody-drug conjugate in prostate cancerYelin Mulati, Qi Shen, Yuke Chen, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Frontiers in Oncology|November 1, 2021
Novel Androgen Receptor Inhibitors in Non-Metastatic, Castration-Resistant Prostate Cancer: A Systematic Review and Network Meta-AnalysisYelin Mulati, Yu Fan, Wei Yu, et al.
Frontiers in Oncology|January 27, 2022
Diagnostic Accuracy of Contemporary Selection Criteria in Prostate Cancer Patients Eligible for Active Surveillance: A Bayesian Network Meta-AnalysisYu Fan, Yelin Mulati, Lingyun Zhai, et al.
International Journal of Biological Sciences|January 3, 2024
ZNF471 Interacts with BANP to Reduce Tumour Malignancy by Inactivating PI3K/AKT/mTOR Signalling but is Frequently Silenced by Aberrant Promoter Methylation in Renal Cell CarcinomaXiaofei Wang, Lin Yao, Zheng Li, et al.
World Journal of Urology|January 23, 2026
P.I. nomogram: an exploratory imaging-derived model for predicting early urinary incontinence following ThuLEPXiao-Da Lan, Rui Jiang, He Wang, et al.
Scientific Reports|July 4, 2025
Characterizing PSMA heterogeneity in prostate cancer and identifying clinically actionable tumor associated antigens in PSMA negative casesYelin Mulati, Qi Shen, Yuxuan Tian, et al.
Theranostics|May 7, 2026
Integrated radio-theranostics using a [<sup>89</sup>Zr]Zr-/[<sup>177</sup>Lu]Lu-labeled B7-H3 antibody-drug conjugate for prostate cancerYongkang Qiu, Tingfei Gu, Tianyao Wang, et al.
Prostate Cancer and Prostatic Diseases|December 24, 2025
Systematic profiling of tumor-associated antigen expression for antibody-drug conjugate in prostate cancerYelin Mulati, Qi Shen, Yuke Chen, et al.
Pageof 1